CD4 mimetic miniproteins: Potent anti-HIV compounds with promising activity as microbicides

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 818-826

  Van herrewege, Yven ^a   Morellato, Laurence ^b   Descours, Anne ^b   Aerts, Laetitia ^a   Michiels, Jo ^a   Heyndrickx, Leo ^a   Martin, Loïc ^b   Vanham, Guido ^a,c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

In vitro activity; Sexual transmission; Vaginal microbicides

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CD4 MIMETIC MINIPROTEIN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; HEPARIN; MICROBICIDE; PHENYLALANINE; PROTEIN M33; PROTEIN M47; PROTEIN M48; PROTEIN M48 HEP; PROTEIN M48 U1; PROTEIN M48 U2; PROTEIN M48 U3; PROTEIN M48D100; PROTEIN M48D30; PROTEIN M48D50; PROTEIN M48T100; PROTEIN M48T30; PROTEIN M48T50; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MONOCYTE; NONHUMAN; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; HIV-1; INHIBITORY CONCENTRATION 50; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDES;

EID: 41149121552     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn042     Document Type: Article

References (40)

1. Lederman MM, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306: 485-7.
2. Fletcher PS, Wallace GS, Mesquita PM et al. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology 2006; 3: 46.
3. Dezzutti CS, James VN, Ramos A et al. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 2004; 48; 3834-44.
4. Pusch O, Kalyanaraman R, Tucker LD et al. An anti-HIV microbicide engineered in commensal bacteria: Secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 2006; 20: 1917-22.
5. Kilmarx PH, van de Wijgert JH, Chaikummao S et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a phase II clinical trial. J Acquir Immune Defic Syndr 2006; 43: 327-34.
6. Howett MK, Neely EB, Christensen ND et al. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother 1999; 43: 314-21.
7. van De Wijgert J, Fullem A, Kelly C et al. Phase 1 trial of the topical microbicide BufferGel: Safety results from four international sites. J Acquir Immune Defic Syndr 2001; 26: 21-2.
8. Van Herrewege Y, Vanham G, Michiels J et al. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob Agents Chemother 2004; 48: 3684-9.
9. Van Herrewege Y, Michiels J, Van Roey J et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004; 48: 337-9.
10. Fletcher P, Kiselyeva Y, Wallace G et al. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 2005; 79: 11179-86.
11. Zussman A, Lara L, Lara HH et al. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003; 17: 653-61.
12. Van Herrewege Y, Michiels J, Waeytens A et al. A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. Antiviral Res 2007; 74: 111-24.
13. Klatzmann D, Champagne E, Chamaret S et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312: 767-8.
14. Martin L, Stricher F, Misse D et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 2003; 21: 71-6.
15. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74: 6087-95.
16. Kawamura T, Cohen SS, Borris DL et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000; 192: 1491-500.
17. Spira Al, Marx PA, Patterson BK et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996; 183: 215-25.
18. Greenhead P, Hayes P, Watts PS et al. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74: 5577-86.
19. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005; 73: 1253-63.
20. Zhu P, Liu J, Bess J, Jr et al. Distribution and three-dimensional structure of AIDS virus envelope spikes, Nature 2006; 441: 847-52.
21. Zanetti G, Briggs JA, Grunewald K et al. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog 2006; 2: 83.
22. Sougrat R, Bartesaghi A, Lifson JD et al. Electron tomography of the contact between T cells and SIV/HIV-1: Implications for viral entry. PLoS Pathog 2007; 3: 63.
23. Bennett A, Liu J, Van Ryk D et al. Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with native viral gp120. J Biol Chem 2007; 282: 27754-9.
24. Huang CC, Stricher F, Martin L et al. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 2005; 13: 755-68.
25. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-7.
26. Peden K, Martin M. Virological and molecular genetic techniques for studies of established HIV isolates. In: Kam J, ed. A Practical Approach to HIV Virology and Immunity. New York, NY: Oxford University Press, 1995; 21-45.
27. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-18.
28. Beirnaert E, Willems B, Peeters M et al. Design and evaluation of an in-house HIV-1 (group M and O)_SIVmnd and SIVcpz antigen capture assay. J Virol Methods 1998; 73: 65-70.
29. Kwong PD, Wyatt R, Majeed S et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000; 8: 1329-39.
30. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4: 199-210.
31. Striche F, Martin L, Barthe P et al. A high-throughput fluorescence polarization assay specific to the CD4 binding site of HIV-1 glycoproteins based on a fluorescein-labelled CD4 mimic. Biochem J 2005; 390: 29-39.
32. Kwong PD, Wyatt R, Robinson J et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-59.
33. Wyatt R, Kwong PD, Desjardins E et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393: 705-11.
34. Li H, Song H, Heredia A et al. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent mini-protein. Bioconjug Chem 2004; 15: 783-9.
35. Li H, Guan Y, Szczepanska A et al. Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins. Bioorg Med Chem 2007; 15 4220-8.
36. Sullivan N, Sun Y, Sattentau Q et al. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glyco-protein: consequences for virus entry and neutralization. J Virol 1998; 72: 4694-703.
37. Zhang W, Canziani G, Plugariu C et al. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Biochemistry 1999: 38: 9405-16.
38. Xie H, Ng D, Savinov SN et al. Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus. J Med Chem 2007; 50: 4898-908.
39. Gauduin MC, Allaway GP, Olson WC et al. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. J Virol 1998; 72: 3475-8.
40. Hu Q, Frank I, Williams V et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199: 1065-75.